RESUMEN
To evaluate Interleukin 1-beta (IL-1ß) serum and mononuclear leucocyte mRNA levels, also rs16944 (-511C/T) genotype, in relation to hyperglycemic normalization in Type 2 diabetes (T2D) patients, we recruited 30 individuals recently T2D diagnosed with hyperglycemia studied at basal time and after 6 and 12 months of the normalization treatment. At basal time, the T polymorphic allele of the rs16944 was associated with lower IL-1ß mRNA expression (p = 0.006); and higher glucose level was positive correlated to IL-1ß protein levels (p = 0.015). After treatment, the individuals showed a significant decrease in glucose level (p = 0.003), but they did not express significant changes in the IL-1ß serum levels. Surprisingly, we observed that the greater decreases in glucose level were associated to increased IL-1ß serum levels (p = 0.040). This is the first follow-up study evaluating IL-1ß mRNA expression and serum levels in hyperglycemic T2D individuals and after glycemic normalization treatment. The current results contribute to the knowledge of the relationship between inflammation and glucose metabolism in T2D.
